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Abstract Mevalonate kinase deficiency or hyper-IgD syn-
drome is a hereditary autoinflammatory syndrome caused by
mutations in the mevalonate kinase gene. In this review, we will
discuss new findings in this disorder that have been published in
the last 2 years. This includes new insights into pathophysiology,
treatment, and the clinical phenotype linked to the genetic defect.
Introduction
The hyperimmunoglobulinemia D and periodic fever syn-
drome (HIDS) is an autoinflammatory disease characterized
by recurrent episodes of fever, cervical lymphadenopathy, he-
patomegaly, splenomegaly, abdominal pain, skin rash, arthral-
gia, and other inflammatory symptoms [1] accompanied by
increased inflammatory markers such as C-reactive protein
(CRP) and serum amyloid A (SAA). Febrile attacks can be
triggered by childhood vaccinations or minor infection, al-
though the triggers for most attacks are unknown. The name
HIDS was derived from the fact that in the first case series,
increased serum levels of immunoglobulin D (IgD) were
found in all patients with this syndrome. Now that the genetic
background is known, the currently more accurate name for
the disorder is mevalonate kinase deficiency (MKD).
MKD is caused by loss of function mutations in the
mevalonate kinase gene (MVK) [2], which encodes for the
protein mevalonate kinase. Mevalonate kinase is the second
enzyme in the common pathway leading to both cholesterol
and non-sterol isoprenoids and is located directly down-
streams of HMG-CoA-reductase. Mevalonate kinase cataly-
ses the phosphorylat ion of mevalonic acid to 5-
phosphomevalonate (Fig. 1). Non-sterol isoprenoid end prod-
ucts are involved in the prenylation of proteins, where either a
farnesyl group or a geranylgeranyl group is attached to a pro-
tein. This process is necessary for adequate protein function.
Deficiency of mevalonate kinase leads to a shortage of inter-
mediate compounds and end products of this pathway.
The level of remaining mevalonate kinase enzyme activity
in MKD determines the clinical phenotype. Apart from the
abovementioned clinical phenotype of HIDS, MKD can also
present as mevalonate aciduria, a severe disease characterized
by neurologic involvement with psychomotor retardation, cer-
ebellar ataxia, and facial dysmorphy besides the inflammatory
symptoms, leading to early death. MKD forms a continuous
spectrum of disease between these two clinical entities. Over-
lapping clinical syndromes are seen with increasing frequen-
cy. As there is no clear border between phenotypes, we will
use the term mevalonate kinase deficiency, which encom-
passes both HIDS and mevalonate aciduria, to describe the
disease in this paper.
In this review, we will discuss new findings in MKD that
have been published between January 1, 2012 and December
31, 2014.
What is new on the pathophysiological mechanism
of MKD?
In the past 30 years, MKD has been proven to be a typical
monogenetic autoinflammatory disease with overproduction
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of the inflammatory cytokine interleukin-1 beta (IL-1β) as
prominent pathophysiological mechanism [3–7]. The impor-
tance of this cytokine in MKD is backed up by the beneficial
effects of IL-1β-targeting drugs such as anakinra in patients
with this disease [8–11].
Most studies on the pathophysiology of MKD are based on
in vitro cellular models with murine [12–14] or human cells
with drug-induced block of the mevalonate kinase pathway
wi th e i t he r HMG-CoA reduc t a se inh ib i t o r s o r
bisphosphonates (Fig. 1). In these models, LPS or other bac-
terial components are used to mimic the inflammatory stimu-
lus needed for the production of IL-1β. Stimulation of mono-
cytes with LPS leads to increased pro-IL-1β transcription via
activation of transcription factor NF-kB [5]. The effects of
bisphosphonates on inflammation in mice were proven not
to be strain-specific [15]. Besides cellular in vitro models,
two in vivo animal models for MKD have been proposed.
The first model uses heterozygoteMVK knockdownmice that
show aMKD-like phenotype with elevated body temperature,
hepatosplenomegaly, and increased serum IgD [16]. With the
use of this model, altered expression of stimulatory and inhib-
itory B7 glycoproteins on lymphocytes and macrophages with
possible altered balance between stimulatory and inhibitory
signals, as well as differences in cell proliferation between
wild-type and knockdownmice, has been found. Interestingly,
in these experiments, a difference between male and female
mice was seen [17], although in humans, no gender-specific
difference in clinical phenotype has been described.
In a second animal model of MKD, Balb/c mice are intra-
peritoneally injected with bisphosphonates 2 or 3 days prior to
inflammatory stimulation followed by decapitation and anal-
ysis of inflammatory markers such as cytokines, peritoneal
exudates, or splenic infiltration [15, 18, 19]. Comparison of
the cytokine profile of these mice with the cytokine profile of
healthy controls and MKD patients showed few discrepancies
between the murine model and human monocytes, with in-
creased IL-6 expression only in MKD patients and mouse-
specific increased anti-TNF-α expression [20]. Extrapolation
of the results from murine models to humans can be
questioned as it has been proven that bisphosphonates might
actually be able to be beneficial inMKD: A single patient with
MKD treated with weekly bisphosphonates because of sec-
ondary osteoporosis showed complete resolution of the febrile
episodes, which returned when the drug was ceased and dis-
appeared again at reintroduction [21]. Thus, the pro-
inflammatory effect of bisphosphonates may differ between
species or between in vitro/in vivo experimental settings.
The link between increased IL-1β secretion and
mevalonate kinase deficiency inMKD is most likely mediated
by defective protein prenylation. In prenylation, non-sterol
isoprenoids, such as farnesyl pyrophosphate (FPP) or
geranylgeranyl pyrophosphate (GGPP) are coupled to a target
protein, affecting its activity or cellular location. In a human
monocytic MKD model, deficiency of GGPP leads to over-
production of IL-1β [22, 6, 23]. The deficiency of GGPP was
shown to lead to defective prenylation of RhoA, rendering this
protein inactive. Inactivity of RhoA results in increased activ-
ity of Rac1 and consequent activation of PKB [24]. Other
small GTPases may also be affected. The Rac1/PI3K/PKB
pathway had been linked to the pathogenesis of MKD earlier
[5]. Liao et al. reported Rac1-independent increased IL-1β
secretion in MKD [23]. Inactivation of RhoA was able to
induce IL-1β mRNA transcription independent of NLRP3-
or caspase-1 activity [24]. The B7 glycoproteins that were
found to be affected in the earlier described murine MKD
model are also prenylation-dependent [17].
Recently, several papers have focused on disrupted mito-
chondrial function in the pathophysiology of MKD. Possible
Fig. 1 Mevalonate kinase
catalyses the phosphorylation of
mevalonic acid to 5-
phosphomevalonate
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involvement of mitochondria was suggested by the observa-
tion that in a murine cell model, inhibition of the mevalonate
kinase pathway by HMG-CoA reductase inhibitors led to in-
creased programmed cell death via caspase-3 and caspase-9,
the latter being activated via an intrinsic mitochondrial path-
way [25]. Mevalonate kinase deficiency leads to formation of
elongated, instable mitochondria due to defective RhoA
prenylation [14, 26, 24]. The aberrant mitochondria would
normally be cleared from the cytosol by autophagia, but in
MKD, clearance of the defective mitochondria is disrupted.
Because of this defect, mitochondrial DNA accumulates in the
cytosol and is able to bind and activate NLRP3, inducing IL-
1β secretion [26]. Reactive oxygen species, but not specifi-
cally mitochondrial reactive oxygen species (mROS), are in-
volved in this [26, 14]. Thus, both NLRP3-dependent as well
as NLRP3-independent routes of IL-1β activation may be
involved in the pathogenesis of MKD [26, 24].
IL-1β is not the only cytokine involved in the inflammato-
ry response in MKD. PBMCs of MKD patients show a sig-
nificantly different pattern of pro-inflammatory cytokine se-
cretion after specific stimulation of several toll-like receptors
(TLRs), including TLR4, TLR2, and nucleotide oligomeriza-
tion domain-containing 2 (NOD2). Apart from IL-1β, there
was increased expression of IL-1α, TNF, and IL-6 compared
to PBMCs of healthy controls. Incubation of PBMCs from
MKD patients with anakinra led to a normalization of cyto-
kine expression (including TNF and IL-6) [11]. Marcuzzi
et al. also observed increased expression of several different
proinflammatory cytokines in their murine model [20]. These
findings fit with the clinical observation that anti-IL-1β-
treatment in MKD is not fully effective in all patients [11].
A probable explanation for the neurologic symptoms of se-
vere MKD was suggested by Marcuzzi et al. In a neuroblasto-
ma cell line, lovastatin was used as inhibitor of the mevalonate
kinase pathway. Incubation of neuroblastoma cells with lova-
statin led to a significant increase in programmed cell death
with increased caspase-3 and caspase-9 activity, and this was
inhibited by the addition of the isoprenoid end product GGOH
[25]. Also, in mice, bisphosphonate treatment leads to
microglial activation and intracerebral NLRP3 expression [15].
The enzyme deficiency in MKD results in an increased
concentration of mevalonic acid, the substrate for mevalonate
kinase, in plasma and urine. In mildly affected patients, this
increase can be subtle, and accurate measurement can be
tricky. Rodrigues et al. developed and validated an improved
LC-MS/MS-based quantification assay for mevalonic acid
which was tested in human as well as in rat samples [48].
What is new on the treatment of mevalonate kinase
deficiency?
The beneficial role of IL-1 targeting drugs as a therapy for
MKD has been clear since the introduction of the IL-1
receptor antagonist anakinra. Anakinra binds the IL-1 recep-
tor, preventing the actions of both IL-1α and IL-1β, and it has
been shown to reduce the clinical and biochemical inflamma-
tion in MKD. It effectively decreases the frequency and sever-
ity of inflammatory attacks when used on a daily basis [8–10].
In patients with infrequent attacks, on-demand treatment (i.e.,
anakinra is started at the first signs of an inflammatory attack
and ceased again after a few days) has been shown to be
effective [8]. The major disadvantage of anakinra is the occur-
rence of painful injection site reactions. A single case report
described clinical deterioration instead of improvement in a
12-year-old MKD patient when anakinra was initiated 2 days
into a febrile attack with resolution of symptoms and inflam-
matory markers when anakinra was stopped again 5 days after
it was started [27]. A possible concomitant infection aggravat-
ed by the IL-1-receptor blockagemight explain these findings.
Canakinumab, a long acting monoclonal antibody directed
against IL-1β has shown to be effective in reducing both fre-
quency and severity in patients with mild and severe MKD in
case reports and observational case series. Galeotti et al. de-
scribe six patients with MKD who were treated with
canakinumab 2–7 mg/kg every 4 to 8 weeks. Three patients
showed partial response with decreased frequency and sever-
ity of the inflammatory attacks. The other half had complete
response, defined as no fever attacks and no inflammatory
syndrome, during 10 to 21 months of treatment [28], and
canakinumab was more effective than anakinra with regard
to inhibiting the inflammatory response with fewer side effects
in these patients [28]. Another patient who received
canakinumab 4 mg/kg every 4 weeks as primary treatment for
suspected MKD showed complete clinical response during
12 months of treatment, although biochemical inflammatory
parameters remained elevated all this time [29]. In the Eurofever
registry, a large international retrospective database on
autoinflammatory diseases including 67 patients with MKD,
complete response (no disease signs or symptoms and normal-
ization of inflammatory markers) on canakinumab was seen in
one of two patients, while the other one responded partially [10].
Most MKD patients benefit from anti-IL-1 therapy. How-
ever, anti-IL-1-resistant disease may occur. In a small number
of case reports of patients unresponsive to anakinra, the effect
of tocilizumab, a humanized monoclonal antibody against the
interleukin-6 (IL-6) receptor, has been detailed. Shendi et al.
treated a young woman in whom anakinra was ineffective
with tocilizumab 8 mg/kg every 4 weeks (the standard dose
scheme in rheumatoid arthritis) and found effective reduction
of clinical and biochemical inflammation [30]. Two additional
MKD patients treated with tocilizumab are described by
Stoffels et al., who also observed reduction of frequency and
severity of the inflammatory attacks, although after several
months of treatment one of these two patients persistently
showed mild inflammatory symptoms in the absence of bio-
chemical inflammatory markers [11].
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Anti-TNF therapy might be effective in MKD, but the ef-
fect is mostly partial and therapy failure and clinical deterio-
ration have been described frequently in patients on infliximab
or etanercept [10]. A beneficial effect of human monoclonal
anti-TNFα antibody adalimumab was seen in a small number
of MKD patients, where the two patients in the Eurofever
registry that were treated with adalimumab showed only par-
tial or no response [10, 31].
Several case reports, including one in the past 2 years, de-
scribe a beneficial effect of hematopoietic stem cell transplan-
tation on the neurologic and inflammatory symptoms in se-
vere mevalonate kinase deficiency [32–34]. Improvement of
cerebral myelinisation on MRI after allogenic stem cell trans-
plantation was seen in one girl [32]. This patient also showed
resolution of spastic diplegia following liver transplantion,
although this finding might be influenced by the start of phys-
iotherapy directly after the transplantation. Liver transplanta-
tion did not influence febrile attacks in this patient [32]. These
results could indicate that stem cell transplantation offers a
curative option for severe MKD, especially for its neurologi-
cal features.
Extending the spectrum of mevalonate kinase deficiency
As previously described, MKD forms a spectrum of disease
and can therefore present with a diversity of symptoms. In the
past 2 years, it became clear that three more or less seemingly
unrelated clinical presentations are associated with mutations
in MVK (Table 1).
A new initial presentation of MKD was described in
two patients with neonatal onset severe ulcerative coli-
tis. In these patients, compound heterozygous mutations
in MVK and increased urinary mevalonic acid excretion
were found. Both patients presented with bloody diar-
rhea and abdominal pain. One of these patients also
suffered from early onset fever; in the other, the first
febrile episode occurred several months after the initial
abdominal symptoms. Treatment with anakinra resulted
in clinical and biochemical improvement in these pa-
tients [35]. A genome-wide association study in six
children with mild to severe early onset colitis and a
proven MVK mutation showed variants that have previ-
ously been linked to IBD in all of them [36], illustrat-
ing a possible genetic relation between MKD and IBD.
IBD-like symptoms can indeed be part of the clinical
phenotype of the HIDS-type of MKD as well.
Other rare or new presentations of MKD that were recently
reported are cyclic neutropenia between febrile attacks in a
young Israelian boy with homozygous V337I mutation [37],
hepatitis [32, 38, 39], and macrophage activation syndrome in
an American girl with compound heterozygous MVK muta-
tions and a perforin polymorphism [38].
Retinitis pigmentosa is a clinical syndrome characterized
by night blindness and peripheral vision loss. Retinitis
pigmentosa has been described previously as a rare and severe
complication of MKD. In a large cohort of retinitis
pigmentosa patients lacking a genetic defect, three patients
harboring homozygous mutations in MVKwere found. These
three patients seemed to have isolated retinitis pigmentosa,
without a clinical phenotype of MKD otherwise, although
two of these patients reported recurrent febrile episodes during
childhood and had current mild symptoms that could beMKD
related. The third patient did not have any signs of MKD.
However, this patient was using a HMG-CoA reductase in-
hibitor because of ischemic heart disease, which may have
influenced the phenotype. Severely decreased serum
mevalonate kinase activity, and increased urinary mevalonic
acid excretion was found in all three patients. Two out of three
showed increased serum IgD concentrations [40].
Disseminated superficial actinic porokeratosis (DSAP) is
an autosomal dominant hereditary skin disease characterized
by annular keratotic lesion predominantly located on sun-
exposed parts of the skin. Heterozygous mutations in MVK
were identified by exome sequencing in several familial and
sporadic DSAP cases [41–43]. Several more case reports have
since appeared [44–46], all of them from patients of Asiatic
origin. Although some of the mutations identified have also
been found in MKD, most mutations were splice site muta-
tions, the studied DSAP patients did not show any clinical
signs of MKD, and porokeratosis is not a known feature of
MKD [41, 44]. In DSAP, no abnormal IgD serum levels have
been described [41]. The effect of the MVK mutations asso-
ciated with DSAP on enzyme activity has not been studied to
date. In a Chinese family with porokeratosis of Mibelli, a
dermatological disease closely related to DSAP, a novel splice
site mutation in MVK was found [47]. A possible causative
link between MVK mutations and porokeratosis is that
mevalonate kinase prevents UVA-induced apoptosis in
keratinocytes [41].
Table 1 Clinical presentations associated with mutations in the MVK
gene
Typical autoinflammatory
diseases
Mevalonic aciduria
Hyperimmunoglobulinemia D and
periodic fever syndrome (HIDS)
Inflammatory phenomena
associated with MKDa
Ulcerative colitis
Neonatal hepatitis
Diseases without systemic
inflammation
Retinitis pigmentosab
Disseminated superficial actinic
porokeratosis (DSAP)
Porokeratosis of Mibelli
a Can be part of severe MKD phenotype and may be the initial presenting
symptom in the absence of fever episodes
b Also, rare symptom of typical MKD
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Conclusion
In the last 2 years, research on MKD has covered a range of
subjects in pathogenesis and therapy. Also, the already broad
spectrum of MKD phenotypes has been extended to include
retinitis pigmentosa, colitis, and DSAP.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unre-
stricted use, distribution, and reproduction in any medium, provided you
give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made.
References
1. van der Meer JW, Vossen JM, Radl J, van Nieuwkoop JA, Meyer
CJ, Lobatto S, van Furth R (1984) Hyperimmunoglobulinaemia D
and periodic fever: a new syndrome. Lancet 1(8386):1087–1090
2. Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser
SD, de Jong JG, Beckmann JS, van der Meer JW, Delpech M
(1999) Mutations in the gene encoding mevalonate kinase cause
hyper-IgD and periodic fever syndrome. International Hyper-IgD
Study Group. Nat Genet 22(2):178–181. doi:10.1038/9696
3. Drenth JP, Goertz J, Daha MR, van der Meer JW (1996)
Immunoglobulin D enhances the release of tumor necrosis factor-
alpha, and interleukin-1 beta as well as interleukin-1 receptor an-
tagonist from human mononuclear cells. Immunology 88(3):355–
362
4. Frenkel J, Rijkers GT, Mandey SH, Buurman SW, Houten SM,
Wanders RJ, Waterham HR, Kuis W (2002) Lack of isoprenoid
products raises ex vivo interleukin-1beta secretion in
hyperimmunoglobulinemia D and periodic fever syndrome.
Arthritis Rheum 46(10):2794–2803. doi:10.1002/art.10550
5. Kuijk LM, Beekman JM, Koster J,WaterhamHR, Frenkel J, Coffer
PJ (2008) HMG-CoA reductase inhibition induces IL-1beta release
through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood
112(9):3563–3573. doi:10.1182/blood-2008-03-144667
6. Kuijk LM, Mandey SH, Schellens I, Waterham HR, Rijkers GT,
Coffer PJ, Frenkel J (2008) Statin synergizes with LPS to induce IL-
1beta release by THP-1 cells through activation of caspase-1. Mol
Immunol 45(8):2158–2165. doi:10.1016/j.molimm.2007.12.008
7. Pontillo A, Paoluzzi E, Crovella S (2010) The inhibition of
mevalonate pathway induces upregulation of NALP3 expression:
new insight in the pathogenesis of mevalonate kinase deficiency.
Eur J Human Genet : EJHG 18(7):844–847. doi:10.1038/ejhg.
2010.9
8. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A,
Frenkel J (2011) On-demand anakinra treatment is effective in
mevalonate kinase deficiency. Ann Rheum Dis 70(12):2155–
2158. doi:10.1136/ard.2011.149922
9. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A
(2005) Effect of etanercept and anakinra on inflammatory attacks in
the hyper-IgD syndrome: introducing a vaccination provocation
model. Neth J Med 63(7):260–264
10. Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C,
Kone-Paut I, Cantarini L, Insalaco A, Neven B, Hofer M, Rigante
D, Al-Mayouf S, Touitou I, Gallizzi R, Papadopoulou-Alataki E,
Martino S, Kuemmerle-Deschner J, Obici L, Iagaru N, Simon A,
Nielsen S, Martini A, Ruperto N, Gattorno M, Frenkel J, Paediatric
Rheumatology International Trials O, The Eurofever/Eurotraps
Project (2013) Treatment of autoinflammatory diseases: results
from the Eurofever Registry and a literature review. Ann Rheum
Dis 72(5):678–685. doi:10.1136/annrheumdis-2011-201268
11. Stoffels M, Jongekrijg J, Remijn T, Kok N, van der Meer JW,
Simon A (2015) TLR2/TLR4-dependent exaggerated cytokine pro-
duction in hyperimmunoglobulinaemia D and periodic fever syn-
drome. Rheumatology 54(2):363–368. doi:10.1093/rheumatology/
keu341
12. Marcuzzi A, Tommasini A, Crovella S, Pontillo A (2010) Natural
isoprenoids inhibit LPS-induced-production of cytokines and nitric
oxide in aminobisphosphonate-treated monocytes. Int
Immunopharmacol 10(6):639–642. doi:10.1016/j.intimp.2010.03.
008
13. Marcuzzi A, Piscianz E, Girardelli M, Crovella S, Pontillo A (2011)
Defect in mevalonate pathway induces pyroptosis in Raw 264.7
murine monocytes. Apoptosis : Int J Programmed Cell Death
16(9):882–888. doi:10.1007/s10495-011-0621-1
14. Tricarico PM, Kleiner G, Valencic E, Campisciano G, Girardelli M,
Crovella S, Knowles A, Marcuzzi A (2014) Block of the
mevalonate pathway triggers oxidative and inflammatorymolecular
mechanisms modulated by exogenous isoprenoid compounds. Int J
Mol Sci 15(4):6843–6856. doi:10.3390/ijms15046843
15. Kleiner G, Celsi F, Tricarico PM, Zacchigna S, Crovella S,
Marcuzzi A (2013) Systemic and neuronal inflammatory markers
in a mouse model of mevalonate kinase deficiency: a strain-
comparative study. In Vivo 27(6):715–722
16. Hager EJ, Tse HM, Piganelli JD, Gupta M, Baetscher M, Tse TE,
Pappu AS, Steiner RD, Hoffmann GF, Gibson KM (2007) Deletion
of a single mevalonate kinase (Mvk) allele yields a murine model of
hyper-IgD syndrome. J Inherit Metab Dis 30(6):888–895. doi:10.
1007/s10545-007-0776-7
17. Hager EJ, Piganelli JD, Tse HM, Gibson KM (2012) Aberrant ex-
pression of costimulatory molecules in splenocytes of the
mevalonate kinase-deficient mouse model of human hyper-IgD
syndrome (HIDS). J Inherit Metab Dis 35(1):159–168. doi:10.
1007/s10545-011-9349-x
18. Marcuzzi A, Pontillo A, De Leo L, Tommasini A, Decorti G, Not T,
Ventura A (2008) Natural isoprenoids are able to reduce inflamma-
tion in a mouse model of mevalonate kinase deficiency. Pediatr Res
64(2):177–182. doi:10.1203/PDR.0b013e3181761870
19. Marcuzzi A, Crovella S, Pontillo A (2011) Geraniol rescues inflam-
mation in cellular and animal models of mevalonate kinase defi-
ciency. In vivo 25(1):87–92
20. Marcuzzi A, Zanin V, Kleiner G, Monasta L, Crovella S (2013)
Mouse model of mevalonate kinase deficiency: comparison of cy-
tokine and chemokine profile with that of human patients. Pediatr
Res 74(3):266–271. doi:10.1038/pr.2013.96
21. Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani
B, Galeazzi M, Rigante D (2013) Weekly oral alendronate in
mevalonate kinase deficiency. Orphanet J Rare Dis 8:196. doi:10.
1186/1750-1172-8-196
22. Mandey SH, Kuijk LM, Frenkel J, Waterham HR (2006) A role for
geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum
54(11):3690–3695. doi:10.1002/art.22194
23. Liao Y-H, Lin Y-C, Tsao S-T, Lin Y-C, Yang A-J, Huang C-T,
Huang K-C, Lin WW (2013) HMG-CoA reductase inhibitors acti-
vate caspase-1 in human monocytes depending on ATP release and
P2X7 activation. J Leukoc Biol 93(2):289–299
24. van der Burgh R, Pervolaraki K, Turkenburg M, Waterham HR,
Frenkel J, Boes M (2014) Unprenylated RhoA contributes to IL-
1beta hypersecretion in mevalonate kinase deficiency model
through stimulation of Rac1 activity. J Biol Chem 289(40):
27757–27765. doi:10.1074/jbc.M114.571810
25. Marcuzzi A, Zanin V, Piscianz E, Tricarico PM, Vuch J, Girardelli
M, Monasta L, Bianco AM, Crovella S (2012) Lovastatin-induced
apoptosis is modulated by geranylgeraniol in a neuroblastoma cell
Semin Immunopathol (2015) 37:371–376 375
line. Int J Dev Neurosci : Off J Int Soc Developmental Neurosci
30(6):451–456. doi:10.1016/j.ijdevneu.2012.06.002
26. van der Burgh R, Nijhuis L, Pervolaraki K, Compeer EB, Jongeneel
LH, van Gijn M, Coffer PJ, Murphy MP, Mastroberardino PG,
Frenkel J, Boes M (2014) Defects in mitochondrial clearance pre-
dispose human monocytes to interleukin-1beta hypersecretion. J
Biol Chem 289(8):5000–5012. doi:10.1074/jbc.M113.536920
27. Shendi HM, Walsh D, Edgar JD (2012) Etanercept and anakinra
can prolong febrile episodes in patients with hyperimmunoglobulin
D and periodic fever syndrome. Rheumatol Int 32(1):249–251. doi:
10.1007/s00296-009-1322-8
28. Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-
Meunier B, Pillet P, Kone-Paut I (2012) Efficacy of interleukin-1-
targeting drugs in mevalonate kinase deficiency. Rheumatology
51(10):1855–1859. doi:10.1093/rheumatology/kes097
29. Tsitsami E, Papadopoulou C, Speletas M (2013) A case of
hyperimmunoglobulinemia d syndrome successfully treated with
canakinumab. Case Rep Rheumatol 2013:795027. doi:10.1155/
2013/795027
30. Shendi HM,Devlin LA, Edgar JD (2014) Interleukin 6 blockade for
hyperimmunoglobulin D and periodic fever syndrome. J Clin
Rheumatol : Pract Rep Rheum Musculoskelet Dis 20(2):103–105.
doi:10.1097/01.RHU.0000442576.41537.de
31. Di Gangi M, Amato G, Converso G, Benenati A, Leonetti C,
Borella E, Doria A, Foti R (2014) Long-term efficacy of
adalimumab in hyperimmunoglobulin D and periodic fever syn-
drome. Isr Med Assoc J 16(10):605–607
32. Chaudhury S, Hormaza L, Mohammad S, Lokar J, Ekong U,
Alonso EM, Wainwright MS, Kletzel M, Whitington PF (2012)
Liver transplantation followed by allogeneic hematopoietic stem
cell transplantation for atypical mevalonic aciduria. Am J
Transplant : Off J Am Soc Transplant Am Soc Transplant Surg
12(6):1627–1631. doi:10.1111/j.1600-6143.2011.03989.x
33. Neven B, Valayannopoulos V, Quartier P, Blanche S, Prieur AM,
Debre M, Rolland MO, Rabier D, Cuisset L, Cavazzana-Calvo M,
de Lonlay P, Fischer A (2007) Allogeneic bone marrow transplan-
tation in mevalonic aciduria. N Engl J Med 356(26):2700–2703.
doi:10.1056/NEJMoa070715
34. Arkwright PD, Abinun M, Cant AJ (2007) Mevalonic aciduria
cured by bone marrow transplantation. N Engl J Med 357(13):
1350. doi:10.1056/NEJMc072002
35. Levy M, Arion A, Berrebi D, Cuisset L, Jeanne-Pasquier C, Bader-
Meunier B, Jung C (2013) Severe early-onset colitis revealing
mevalonate kinase deficiency. Pediatrics 132(3):e779–e783. doi:
10.1542/peds.2012-3344
36. Bianco AM, Girardelli M, Vozzi D, Crovella S, Kleiner G,
Marcuzzi A (2014) Mevalonate kinase deficiency and IBD: shared
genetic background. Gut 63(8):1367–1368. doi:10.1136/gutjnl-
2013-306555
37. Parvaneh N, Ziaee V, Moradinejad MH, Touitou I (2014)
Intermittent neutropenia as an early feature of mild mevalonate
kinase deficiency. J Clin Immunol 34(1):123–126. doi:10.1007/
s10875-013-9955-5
38. Schulert GS, Bove K, McMasters R, Campbell K, Leslie N, Grom
AA (2014) Mevalonate kinase deficiency associated with recurrent
liver dysfunction, macrophage activation syndrome and perforin
gene polymorphism. Arthritis Care Res. doi:10.1002/acr.22527
39. von Linstow M-L, Rosenfeldt V (2014) Neonatal hepatitis as first
manifestation of hyperimmunoglobulinemia d syndrome. Case Rep
Pediatr 2014:936890
40. Siemiatkowska AM, van den Born LI, van Hagen PM, Stoffels M,
Neveling K, Henkes A, Kipping-Geertsema M, Hoefsloot LH,
Hoyng CB, Simon A, den Hollander AI, Cremers FPM, Collin
RWJ (2013)Mutations in the mevalonate kinase (MVK) gene cause
nonsyndromic retinitis pigmentosa. Ophthalmology 120(12):2697–
2705
41. Zhang S-Q, Jiang T, Li M, Zhang X, Ren Y-Q, Wei S-C, Sun L-D,
Cheng H, Li Y, Yin X-Y, Hu Z-M, Wang Z-Y, Liu Y, Guo B-R,
Tang H-Y, Tang X-F, Ding Y-T, Wang J-B, Li P, Wu B-Y, WangW,
Yuan X-F, Hou J-S, HaW-W,WangW-J, Zhai Y-J,Wang J, Qian F-
F, Zhou F-S, Chen G, Zuo X-B, Zheng X-D, Sheng Y-J, Gao J-P,
Liang B, Li P, Zhu J, Xiao F-L, Wang P-G, Cui Y, Li H, Liu S-X,
GaoM, Fan X, Shen S-K, ZengM, SunG-Q, XuY, Hu J-C, He T-T,
Li Y-R, Yang H-M, Wang J, Yu Z-Y, Zhang H-F, Hu X, Yang K,
Wang J, Zhao S-X, Zhou Y-W, Liu J-J, Du W-D, Zhang L, Xia K,
Yang S, Wang J, Zhang X-J (2012) Exome sequencing identifies
MVK mutations in disseminated superficial actinic porokeratosis.
Nat Genet 44(10):1156–1160
42. Dai J, Chen M, Fu X, Yu Y, Shi Z, Yu C, Wang G, Tian H, Liu H,
Zhang F (2013) Mutation analysis of the MVK gene in Chinese
patients with disseminated superficial actinic porokeratosis. J
Dermatol Sci 72(3):320–322. doi:10.1016/j.jdermsci.2013.07.011
43. Zhou Y, Liu J, Fu X, Yu Y, Shi B, Yu G, Shi Z, Wu W, Pan F, Tian
H, Liu H, Zhang F (2013) Identification of three novel frameshift
mutations of the MVK gene in four Chinese families with dissem-
inated superficial actinic porokeratosis. Br J Dermatol 169(1):193–
195. doi:10.1111/bjd.12224
44. Lu WS, Zheng XD, Yao XH, Zhang LF, Wang MQ, Jiang FX,
Zhang SP, Hu B (2014) A novel MVK missense mutation in one
Chinese family with disseminated superficial actinic porokeratosis.
Mol Biol Rep 41(11):7229–7233. doi:10.1007/s11033-014-3609-4
45. ZhouMS, Xie HF, ChenML, JianD, Liu FF, Chen X, ShenN, Si N,
Li J (2014) A novel mutation for disseminated superficial actinic
porokeratosis in the MVK gene. Br J Dermatol 171(2):427–429.
doi:10.1111/bjd.12947
46. Lu WS, Zheng XD, Yao XH, Zhang LF, Hu B, Lu YJ (2014)
Detection of a novel missense mutation in the mevalonate kinase
gene in one Chinese family with DSAP. Int J Clin Exp Pathol 7(2):
728–732
47. Zeng K, Zhang QG, Li L, Duan Y, Liang YH (2014) Splicing
mutation in MVK is a cause of porokeratosis of Mibelli. Arch
Dermatol Res 306(8):749–755. doi:10.1007/s00403-014-1465-7
48. Rodrigues AVM, Maggs JL, McWilliam SJ, Pirmohamed M, Coen
M, Wilson ID, Park BK, Antoine DJ (2014) Quantification of uri-
nary mevalonic acid as a biomarker of HMG-CoA reductase activ-
ity by a novel translational LC-MS/MS method. Bioanalysis 6(7):
919–933
376 Semin Immunopathol (2015) 37:371–376
